Clinical Trial

Cold Atmospheric Plasma for Moderate-to-severe Acne Vulgaris Study

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 2, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Acne vulgaris is a common, chronic inflammatory skin disease with complex pathogenesis and limited therapeutic options, especially for moderate-to-severe cases. Standard treatments-including topical and oral agents-are often constrained by side effects, antimicrobial resistance, and treatment resistance. Cold atmospheric plasma (CAP), a novel technology that generates reactive oxygen and nitrogen species, has demonstrated antimicrobial and tissue-regenerative properties in dermatology, but robust clinical evidence in acne management remains scarce. Existing data suggest promising efficacy and safety, yet its use in moderate-to-severe acne vulgaris has not been adequately investigated. This study aims to evaluate the efficacy and safety of two self-developed CAP devices as a potential innovative therapy for moderate-to-severe acne vulgaris.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-30.
Status change: Not Yet Recruiting → Recruiting 2025-12-30
Trial Details
NCT Number NCT07056673
Lead Sponsor Shenyang Medical College
Collaborators: the 989th Hospital of Chinese People's Liberation Army Joint Logistic Support Force
Conditions Acne Vulgaris
Enrollment 220 participants
Start Date 2025-07-26
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-12-20 (estimated)
Updated on ClinicalTrials.gov 2026-01-02